Lyme Disease Antibodies

Lyme disease is the most common tick-borne illness in the United States, with an estimated 476,000 people diagnosed and treated each year. The bacteria responsible, Borrelia burgdorferi, enter the body through the bite of an infected blacklegged tick, and the infection can affect the joints, heart, and nervous system if left untreated. The challenge is that many people never notice the tick bite, and the characteristic expanding rash (called erythema migrans, which sometimes takes a bull's-eye shape) develops in only about 70 to 80 percent of cases.

This panel measures the two classes of antibodies your immune system produces when it encounters Borrelia burgdorferi. Testing both together is what gives you a meaningful answer, because each antibody class tells a different part of the story: one reflects your body's first response to a new infection, while the other reflects a more mature, lasting immune reaction.

What This Panel Reveals

Your immune system responds to Lyme bacteria in a predictable sequence. First, it produces a fast-acting but short-lived antibody called Immunoglobulin M (IgM). This antibody typically becomes detectable in the blood within one to two weeks after symptoms begin, peaking around six to eight weeks after the initial infection.

A few weeks later, the immune system shifts to producing a more durable antibody called Immunoglobulin G (IgG). IgG usually appears four to six weeks after symptom onset and can remain detectable for months, years, or even decades after the infection has been successfully treated. This persistence is normal and does not mean the infection is still active.

By measuring both antibody classes in the same blood draw, this panel helps answer three questions at once. Is there evidence of any exposure to Borrelia burgdorferi? Does the antibody pattern suggest a recent infection versus one that happened weeks or months ago? And does the combination of results warrant confirmatory testing or treatment?

Why Both Antibodies Matter Together

Neither antibody tells the full story on its own. IgM appears early, which makes it useful for catching new infections, but it also has a high false-positive rate. Conditions like Epstein-Barr virus infection (the virus behind mononucleosis), certain autoimmune diseases, and even other bacterial infections can trigger a positive Lyme IgM result when no Lyme infection exists. One study found that a significant proportion of positive IgM results in clinical practice were ultimately false positives.

IgG is far more specific to Borrelia burgdorferi, especially when confirmed by a second-step laboratory test called a Western blot, which checks for antibodies to specific parts of the Lyme bacterium. But IgG takes longer to develop, so a negative IgG in the first few weeks of illness does not rule out Lyme disease. It simply means the immune system has not yet had enough time to mount a full IgG response.

The combination reveals what neither test alone can. A positive IgM with a negative IgG suggests a very recent infection, typically within the first four to six weeks. A positive IgG (with or without IgM) points to an infection that has been present for at least several weeks. And two negative results, in a person who has had symptoms for more than six weeks, make active Lyme disease very unlikely.

How to Read Your Results Together

The interpretation of Lyme antibody results depends heavily on timing, specifically how long you have had symptoms. The Centers for Disease Control and Prevention (CDC) recommends that a positive IgM result should only be considered diagnostically meaningful if symptoms have been present for 30 days or fewer. After that window, a positive IgM alone is more likely to be a false positive than evidence of active Lyme disease.

These results are a screening step, not a final diagnosis. The CDC's recommended approach uses two tiers of testing: this panel serves as the first tier, and positive or borderline results should be followed by confirmatory testing, either a Western blot or a second, different antibody test (called an immunoassay). A 2019 CDC update now allows two separate antibody tests (using different target proteins) to replace the traditional antibody-test-plus-Western-blot sequence, which improves turnaround time without sacrificing accuracy.

When Results Can Be Misleading

Timing is the single biggest source of confusion. If you test too early, within the first one to two weeks of a tick bite, both IgM and IgG may be negative simply because the immune system has not yet produced enough antibodies to detect. The ability of standard two-step antibody testing to detect early localized Lyme disease is only about 30 to 40 percent. By the time the infection has spread beyond the skin to joints, the heart, or the nervous system, detection rates rise to 70 to 87 percent. In late Lyme disease, such as Lyme arthritis, detection rates approach 100 percent.

IgM false positives deserve special attention. Epstein-Barr virus (the virus behind mononucleosis), rheumatoid factor (an immune protein linked to autoimmune conditions), syphilis, and certain autoimmune conditions can all cause a positive Lyme IgM. This is why a standalone positive IgM, particularly in someone whose symptoms have lasted more than 30 days, should not be treated as proof of Lyme disease without confirmatory testing.

IgG persistence after treatment is another common source of confusion. Because IgG antibodies can remain positive for 10 to 20 years or longer after successful treatment, a positive IgG does not mean you currently have an active infection. Antibody testing cannot be used as a test of cure. If you were treated for Lyme disease in the past, your IgG may still be positive even though the bacteria are long gone.

Tracking Over Time

Serial testing is most valuable when the first set of results is negative but clinical suspicion for Lyme remains high. If you were bitten by a tick in an area where Lyme disease is common and develop symptoms like fever, fatigue, or joint pain, a negative result drawn in the first two weeks should be repeated two to four weeks later. The second draw often captures the rising IgM or newly appearing IgG that the first draw missed.

For people who have been treated for Lyme disease, repeat testing is generally not recommended to confirm cure. Antibody levels do not reliably correlate with treatment success, and a persistently positive IgG can cause unnecessary anxiety. Clinical improvement, not antibody levels, is the best measure of successful treatment.

If you live in a high-risk area (the Northeast, mid-Atlantic, or upper Midwest) and spend time outdoors, annual screening is reasonable during tick season. Even a single baseline result gives you a reference point: if you later develop symptoms and test positive, knowing your prior status helps distinguish a new infection from old antibodies.

What to Do with Your Results

If both results are negative and you have had symptoms for fewer than two weeks, do not assume you are in the clear. Retest in two to four weeks. If both results are negative after six or more weeks of symptoms, Lyme disease is very unlikely and other diagnoses should be explored.

If either result is positive or borderline, confirmatory testing is the next step. Ask for a Western blot or a second antibody test using different target proteins. Do not begin treatment based on a single positive screening result alone, unless a physician determines the clinical picture is highly consistent with Lyme disease (such as a classic bull's-eye rash with a recent tick bite in a region where Lyme is common).

Because the same tick that transmits Borrelia burgdorferi can also carry other pathogens, consider testing for co-infections if your Lyme results are positive. Babesia microti, Anaplasma phagocytophilum, and Ehrlichia are all transmitted by the same blacklegged tick, and co-infections occur in roughly 2 to 12 percent of Lyme disease cases. Co-infections can alter symptom severity and treatment approach.